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The long-term outcome following cardiac valve replacement 
is primarily determined by three factors: irreversible cardiac 
and pulmonary pathology secondary to the valvular disease 
(especially left ventricular myocardial hypertrophy and de- 
generation, and pulmonary vascular disease), pre-existing 
cardiac disease, including congenital lesions and coronary 
arterial atherosclerotic occlusions, and prosthesis-host inter- 
actions. For most of the approximately 40,000 patients who 
undergo valve replacement each year in the United States, 
prosthesis-associated pathology is a a major determinant of 
prognosis. In this article, the significance, morphology, and 
pathogenesis of the major complications and other alter- 
ations during function of mechanical, bioprosthetic, and al- 
lograft valves are reviewed. Other reviews of pathologic 
considerations in cardiac valve replacement are available 
(l-7). 
Structure and Function of Heart 
Valve Substitutes 
Heart valve prostheses respond passively to pressure and 
flow changes within the heart, and are generally classified 
into two types: mechanical and tissue. Mechanical valves 
are composed of synthetic, nonphysiological materials. In 
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contrast, tissue valves are composed, at least in part, of 
animal or human tissue. Bioprosthetic valves are usually 
fabricated from chemically-preserved (usually cross-linked) 
animal tissue, mounted on a prosthetic frame (stent). The 
other important tissue valve type is the human aortic valve 
allograft, processed but not cross-linked, that is implanted 
directly into the aortic root without a stent. Thus, although 
unmounted allografts can only be used as aortic valve re- 
placements, stent-mounted allografts can be used to replace 
the mitral valve, and mechanical or bioprosthetic valves can 
be used in either site. Detailed descriptions of specific mod- 
els of valve substitutes are available (8). 
The Starr-Edwards caged-ball valve, Bjork-Shiley and 
Hall-Medtronic tilting-disk valves, and St. Jude Medical 
bileaflet tilting-disk valve have been the most widely used 
mechanical prostheses. The latter comprises approximately 
one-half of valve replacements done today. Three basic 
components constitute a mechanical valve prosthesis: the 
rigid, mobile, occluder (poppet) around which blood must 
flow, the cagelike superstructure that guides and restricts 
poppet motion, and the valve body or base. Most caged-ball 
valve occluders are composed of silicone rubber, but con- 
temporary tilting-disk valve occluders are coated with py- 
rolytic carbon, a material with high strength, low propensity 
toward wear and fatigue, and high thromboresistance. Me- 
chanical valve cages are constructed of nearly pure titanium 
(e.g., Hall-Medtronic) or cobalt-chromium alloy (e.g., 
Starr-Edwards, Bjork-Shiley). Some designs have carbon 
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disks and supports (St. Jude). Blood flow through a mechan- 
ical valve prosthesis must course around the poppet; thus, 
these valves are somewhat obstructive to forward flow and 
frequently have areas of stasis distal to the orifice. The 
combination of stasis and nonphysiological surfaces yields a 
tendency toward thrombus formation; chronic anticoagula- 
tion therapy is thereby mandatory in patients with mechani- 
cal valves (9,lO). 
Bioprosthetic heart valves generally have better hemody- 
namic efficiency and thromboresistance than mechanical 
valves. Flexible, trileaflet, biological tissue valves have a 
central orifice analogous to natural valves. Tissue valves are 
heterografts/xenografts (e.g., porcine aortic valve or bovine 
pericardial bioprostheses), homografts/allografts (e.g., aor- 
tic valves from either human cadavers or hearts removed at 
transplantation, with or without an aortic sleeve as a con- 
duit), or autografts (e.g., composed of fascia lata or peri- 
cardium, or the patient’s own pulmonary valve transplanted 
to the aortic root). The preferred terminology is xenograft- 
allograft-autograft. Detailed terminology germane to tissue 
heart valves is summarized in reference 5. Stent-mounted 
porcine aortic valve bioprostheses, fabricated from a pig 
aortic valve preserved in glutaraldehyde (0.2% for the Han- 
cock and 0.6% for the Carpentier-Edwards). are widely used 
(presently approximately one-third of all valve replace- 
ments). In porcine bioprosthetic valves, the natural cuspal 
attachments to the aortic wall are maintained intact. Since 
the right coronary cusp of a pig (but not human) aortic valve 
is partially supported by septal myocardium, a porcine valve 
has a muscular shelf which extends into the right coronary 
cusp. This muscle can prevent full-opening of the cusp, be 
a site at which inflammation or tearing can occur, and/or aid 
in orienting the valve for analysis. Valve obstruction related 
to impaired opening of the right coronary cusp can be of 
importance in a porcine bioprosthesis of relatively small 
size. A modified orifice Hancock prosthesis for small sizes 
has a cusp without a muscular ridge substituted from another 
valve, as a means of widening the valve inlet area (11). 
Pericardial valves were used in the last decade but are not 
presently implanted in the United States. Each cusp of a 
pericardial valve is an individual piece of glutaraldehyde- 
treated parietal pericardium (usually of bovine origin) that is 
attached to the frame. Various designs of pericardial bio- 
prostheses differ widely in their method of mounting the 
tissue on the frame. 
Cuspal structure and hence physical properties of porcine 
aortic valve and bovine pericardium are different (4,5,12- 
14). The structure of natural aortic valve cusps is highly 
specialized for function. Material properties in the plane of 
the tissue are anisotropic (not the same in all directions), 
reflecting the nonrandom orientation of architectural ele- 
ments that effectively transmits stress to the aorta. Moreover, 
aortic valve cusps (porcine or other species) have three lay- 
ers: the predominantly collagenous ventricularis, near the 
inflow surface; the central spongiosa, with loosely arranged 
collagen and abundant amorphous extracellular matrix, and 
the fibrosa, with densely packed collagen, facing the outflow 
surface. In contrast, pericardial tissue is a relatively homoge- 
neous sheet of laminated collagen without clear layers; prop- 
erties are similar in all directions (isotropic). Generally, the 
smooth side of the pericardium (formerly the serosa) forms 
the cuspal outflow aspect and the rough surface is the inflow. 
A fabric sewing cuff (usually Dacron) that surrounds the 
base of both mechanical and tissue prostheses facilitates 
suturing the device into the surgically prepared annulus. In 
most cases, organized thrombus or fibrous tissue derived 
from the adjacent myocardium or aortic wall ultimately cov- 
ers the rough cloth surface. The tissue-valve interface is 
sealed by adherent tissue in most cases, but the strength of 
the valve-tissue bond is primarily provided by the sutures. 
Although sewing cuff configurations differ slightly for 
semilunar and atrioventricular sites, prosthetic valves used 
in either site are otherwise virtually identical. 
Prosthesis-Related Complications 
Within 10 years postoperatively, valve-related complica- 
tions occur in approximately 50% or more of patients having 
previously and currently used substitute valves (15). Reoper- 
ations, almost always necessitated by valve-related complica- 
tions, presently account for approximately 20% of all valve 
surgery. Furthermore, many patients die from prosthesis com- 
plications; prosthesis-related events cause approximately half 
of late deaths (16). Valve prosthesis pathology revealed by 
autopsy is often clinically unappreciated. Nevertheless, al- 
though most large studies show little difference in overall 
valve-related complication rates between mechanical pros- 
theses and bioprostheses at 10 years, the frequency and, in 
some cases, the nature of specific valve-related complications 
varies widely with the type, model and site of the replacement 
device (as well as with patient characteristics) (4). 
The most frequent valve-related complications in patients 
with mechanical or bioprosthetic valves are thromboembolic 
problems (including anticoagulant-related hemorrhage), in- 
fective endocarditis, paravalvular leak, intrinsic degradative 
dysfunction, and extrinsic interference with function, usu- 
ally by tissue overgrowth (Table 1) (17). The causes of 
failure of 112 consecutive porcine bioprostheses and 45 
mechanical valve prostheses surgically removed at our hos- 
pital during 1980-1985 included thrombosis (9%), tissue 
overgrowth (5%), endocarditis (16%), paravalvular leak 
(1 l%), and degenerative dysfunction (53%) (18). Thrombo- 
sis, a major cause of mechanical valve dysfunction (18% of 
their failures), was infrequent with bioprostheses. In con- 
trast, 74% of removed bioprostheses had primary tissue de- 
generation. Thus, in selecting a substitute valve for a 
specific patient, a surgeon generally weighs the risks of 
thromboembolic complications of mechanical prostheses 
versus the limited long-term durability of bioprostheses. 
Moreover, thromboembolic complications are frequently 
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catastrophic and fatal. In contrast, bioprosthetic valve dys- 
function infrequently causes precipitous clinical deteriora- 
tion (only 5 to 10% of patients require reoperation emer- 
gently) (19). Patients with intrinsic bioprosthetic valve 
failure that is recognized promptly can usually be reoperated 
with an operative mortality not substantially higher than that 
of primary valve replacement surgery (20). 
Thromboembolic complications. Thromboembolic 
complications include thrombosis, thromboembolism, and 
anticoagulation-related hemorrhage. Thrombotic occlusion 
and thromboemboli can occur with all currently available 
types of prostheses, at rates of 1 to 4% per patient-year; 
actuarial freedom from thrombosis or thromboembolism at 
10 years for patients with either porcine bioprostheses (usu- 
ally without anticoagulation) or tilting disk prosthetic valves 
(with anticoagulation) is typically 70 to 80% (9,15). The risk 
of thromboembolism depends on the specific prosthesis 
used and adequacy of anticoagulation (particularly high in 
poorly anticoagulated patients with mechanical valves), car- 
diac rhythm (increases with atria1 fibrillation), and anatomic 
site of valve replaced (mitral > aortic). Thromboembolic 
complications occur most frequently in the first postopera- 
tive year, in part due to thrombogenicity of the valve sewing 
ring prior to tissue incorporation. Nevertheless, traditional 
chronic oral anticoagulation carries a risk of hemorrhage, 
particularly retroperitoneal, gastrointestinal or cerebral, with 
a frequency approximately 4% per patient year, of which 15 
to 25% of events are fatal (21). Consequently, there is con- 
siderable interest in developing less intense anticoagulation 
regimens. Although customary practice aims for maintain- 
ing the prothrombin time at 1.5 to 2.5 times normal, recent 
studies suggest that a target ‘of 1.3 to 1.5 times normal 
maintains low rates of thromboembolism without excessive 
hemorrhagic risk (22). 
prosthetic heart valve thrombi, either red (fibrin) or white 
(platelet), can impair occluder opening or closing or gen- 
Figure 1. Prosthetic valve thrombosis. A. Aortic Bjork-Shiley 
tilting disk valve prosthesis, viewed from distal (outflow) aspect, 
demonstrating localization of thrombus to outflow strut near minor 
orifice, the site of flow stasis (arrow). B. Porcine aortic valve 
prosthesis, from distal (outflow) aspect, demonstrating thrombotic 
deposits in two of three sinuses of Valsalva. 
erate thromboemboli to distal arterial beds. Clinically- 
detectable thromboemboli most frequently (over 80%) in- 
volve the central nervous system. Since the lack of adjacent 
vascular tissue retards typical histologic organization, bio- 
prosthetic or mechanical valve-associated thrombi are fri- 
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able for extended periods. Similarly, determination of dura- 
tion of a thrombus on a prosthesis is nearly impossible. 
The relative propensity for and sites of thrombus on 
specific valve prostheses are determined by surface throm- 
bogenicity, hypercoagulability, and locally static blood flow 
(Virchow’s triad) (23). Valve sites where thrombi occur are 
associated with local hemodynamic disturbances, and de- 
signs having increased turbulence or well-defined regions of 
stasis yield higher rates of thromboembolism. For example, 
thrombi/thromboemboli arise at the cage apex of a caged- 
ball prosthesis, a region of considerable flow abnormality 
(24), in contrast, a tilting disk prosthesis is particularly sus- 
ceptible to thrombus formation in a stagnation zone in the 
minor orifice of the outflow region (Fig. 1A) (25). Throm- 
botic deposits on the cusps of bioprostheses involve one or 
more of the prosthetic sinuses of Valsalva (Fig. 1B); in most 
cases, no causal cuspal pathology can be demonstrated (26). 
Since platelet deposition dominates initial blood-surface in- 
teraction when valves and other cardiovascular devices are 
exposed to blood at high fluid shear stresses (27-30) an- 
tiplatelet agents are often administered in conjunction with 
anticoagulants (lo,3 1,32). 
Prosthetic valve endocarditis. Infective endocarditis is 
infrequent (1 to 6% of patients with valve replacements), but 
serious (over 50% mortality) (33-35). Patients requiring 
valve replacement for native valve endocarditis frequently 
develop prosthetic valve endocarditis with the original or- 
ganism. Infection rates of mechanical valves and bioprosthe- 
ses are approximately the same. Complications of prosthetic 
valve endocarditis include embolization of vegetations, con- 
gestive heart failure secondary to valvular obstruction or re- 
gurgitation caused by bulky vegetations, or the conse- 
quences of local tissue destruction. 
Similar to other infections involving biomaterials, pros- 
thetic valve endocarditis is resistant to host defense mecha- 
nisms and antibiotics, and thereby difficult to cure medically 
(4,33). Infections of mechanical prostheses are almost al- 
ways localized to the prosthesis-tissue interface at the 
sewing ring, causing a ring abscess, since synthetic biomate- 
rials (polymers, metals, carbons) generally cannot support 
bacterial or fungal growth (Fig. 2A) (36,37). The resultant 
tissue destruction may induce separation (dehiscence) of the 
prosthesis from the annulus, with regurgitation of blood 
around the prosthesis (paravalvular or paraprosthetic leak), 
or cause septic pericarditis, pseudoaneurysm, or complete or 
partial interference with atrioventricular conduction. Rarely, 
mechanical valve infection is confined to tissue associated 
with the valve superstructure or poppet (38). 
Bioprosthetic valve endocarditis can be either localized to 
the prosthesis sewing ring and complicated by ring abscess, 
or confined to the cuspal tissue (Fig. 2B), often with tearing, 
perforation, or destruction leading to valve incompetence 
(39,40). Cusps of bioprosthetic valves with endocarditis of- 
ten have deep clusters of organisms with few inflammatory 
cells. Degenerating bacteria and inflammatory cells within 
cuspal vegetations of bioprosthetic valve endocarditis can 
undergo mineralization (extrinsic calcification) (Fig. 2C), 
often in a characteristic pattern that can rapidly suggest the 
diagnosis (Fig. 2D) (5). 
Prosthetic valve endocarditis is generally classified as 
early (within 60 days following valve replacement) or late 
(after 60 days), with etiology, risk factors, and causative 
microorganisms different in each of these time periods. Or- 
ganisms comprising normal skin flora predominate in early 
infections, emphasizing the importance of both valve con- 
tamination during implantation and early postoperative in- 
fection. Late infections are more likely to be precipitated by 
bacteremia associated with poor dental hygiene, dental or 
surgical procedures, or extracardiac pyogenic infections. 
The high frequency of staphylococcal infection on pros- 
thetic valves (Staphylococcus epidermidis, Staphylococcus 
aureus), particularly in early cases, contrasts with the rela- 
tively low frequency of these organisms in natural valve 
endocarditis; streptococci, gram-negative bacilli and fungi 
also are prevalent. In about 15% of cases, a causative organ- 
ism cannot be cultured. Although some of these infections 
could be caused by anaerobes, culture-negative prosthetic 
valve endocarditis has been recently related to legionella 
(41) and Q fever (42). 
Paravalvular leak (dehiscence, paraprosthetic leak) 
(Fig. 3). Early dehiscence is usually the result of technical 
error or separation of sutures from a pathologic annulus 
when valve replacement was done for endocarditis with ring 
abscess, myxomatous degeneration or calcified aortic valve 
or mitral annulus (43). In contrast, late, small paravalulvar 
leaks are usually caused by tissue retraction from the sewing 
ring between sutures during healing. Small periprosthetic 
defects are often clinically inconsequential; large tears can 
aggravate or cause hemolysis or heart failure. A valve re- 
moved for paravalvular leak appears unremarkable to the 
surgical pathologist; detection at autopsy may require care- 
ful probing. 
Durability Considerations 
Prosthetic valve failure is frequently precipitated by the 
limited durability of biomaterials. Specific failure modes 
vary widely for mechanical valves and bioprostheses, and 
frequently, for specific types of each, for prostheses utilizing 
different materials or design features, or for the same model 
placed in the aortic rather than the mitral site (4). 
Mechanical prostheses. Silicone elastomeric ball oc- 
eluders of early caged-ball prostheses absorbed blood lipids, 
causing swelling, distortion, cracking, and embolization of 
poppet material or abnormal poppet movement (ball vari- 
ance), particularly in the aortic position (Fig. 4A) (44). 
Lipid-related ball variance was subsequently eliminated by 
changes in elastomer fabrication in 1964. With cloth cov- 
ered, caged-ball valves used to provide a substrate for tissue 
overgrowth, abrasion by the occluder often induced frag- 
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Figure 2. Prosthetic valve infective endocarditis. A. Ventricular 
view of mitral tilting disk prosthesis in patient dying of infective 
endocarditis. Large bulky vegetations consisting of bacterial or- 
ganisms and platelet/inflammatory cell/fibrin thrombus cover part 
of the sewing ring and form an abscess within tissue of the annulus 
(arrow) (Reproduced by permission from Schoen FJ. Cardiac valve 
prostheses: pathological and bioengineering considerations. J. Car- 
diac Surg 1987; 2:65-108. 0 1987, Futura Publishing Company.) 
B. Bioprosthetic bacterial endocarditis involving cusps, viewed 
from inflow aspect; large vegetations are apparent. (Reproduced by 
permission from Schoen FJ and Hobson CE Anatomic analysis of 
removed prosthetic heart valves: causes of failure of 33 mechanical 
valves and 58 bioprostheses, 1980-1983. Hum Path01 1985; 
16549-559. 0 1985, W.B. Saunders.) C. Photomicrograph of 
calcified endocarditic vegetation on porcine bioprosthetic valve 
(H/E x 175). D. Radiograph of infected porcine bioprosthetic 
valve with calcified vegetations, demonstrating diffuse distribution 
of calcific deposits characteristic of endocarditis. 
Figure 3. Paravalvular leak, mitral prosthesis, viewed from left 
atrium (probe in defect). (Reproduced by permission from Schoen 
FJ. Pathology of caridac valve replacement. In: Morse, D, Steiner 
RM, Femandez J, eds. Guide to Prosthetic Cardiac Valves. New 
York: Springer Verlag, 1985:209-238.) 
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mentation of cloth, thrombosis, fibrous overgrowth and re- 
sultant ball entrapment (models with metal poppets), or pop- 
pet escape (in aortic, but not mitral, models with silicone 
occluders, due to mutual cloth-poppet abrasive wear) (Fig. 
4B) (45,46). Nevertheless, structural failure of presently 
used caged-ball prostheses is rare. Caged-disk valves with 
plastic disks suffered disk wear and resultant valve incom- 
petence, and are no longer used (47,48); plastic-coated 
stents can also wear down (Fig. 4C). ‘Since microfragments 
of worn nonphysiologic material may embolize systemi- 
cally, demonstration of foreign body granulomas on biopsy 
of the liver or other organs may aid the recognition of ball 
or disk variance (49). 
Contemporary tilting disk designs with pyrolytic carbon 
occluders, with or without carbon cage components, have 
generally favorable durability. Fractures of metallic or car- 
bon valve components and escape of parts from such valves 
rarely occur. (50-52). However, in a specific cohort of 
Bjork-Shiley 60 and 70” convexo-concave (C-C) heart 
valves, the welded outlet strut has fractured and separated 
from the valve, leading to disk escape that is frequently fatal 
(Fig. 4D). Over 300 such cases are known; in each fractured 
valve, the previously completely machined housing (inte- 
gral) was replaced by a housing in which the outflow strut 
was welded to the housing. Fatigue failure of the welded 
metallic joint likely precipitates the fracture of this valve 
(53,54). This problem is discussed in detail below. 
In contrast to the free disk rotation of contemporary tilting 
disk valves, bileaflet disk valves have a fixed pivot point at 
the periphery of each disk; the configuration varies with 
specific manufacturer and design. Fractures of components 
of the St. Jude valve are rare; however, at least 17 cases of 
leaflet escape from the Edwards-Duramedics bileaflet valve 
have been reported (Fig. 4E) (55). Detailed pathologic stud- 
ies of removed valves not suffering overt structural dysfunc- 
tion may be useful in predicting long-term durability 
(56,57). 
Bioprostheses. The major cause of bioprosthetic valve 
dysfunction is primary tissue failure, especially when it is 
related to cuspal mineralization (58-61). Noninfective tissue 
degeneration (primary tissue failure) of glutaraldehyde-pre- 
treated porcine bioprostheses is strongly time dependent. In 
adults, less than 1% of valves implanted for 5 years have 
failed, 20 to 30% fail within 10 years, and more than half are 
no longer functional by 15 years postoperatively. Regurgita- 
tion through tears forming adjacent to calcific nodules is the 
most frequent failure mode (Fig. 5A); pure calcific stenosis 
(Fig. 5B) and noncalcific cuspal defects are less frequent 
(1,4,61); rarely, important emboli arise from calcific valves 
(Fig. 5C) (62). Noncalcific tissue tears, revealed by scanning 
electron microscopy as fraying and disruption of collagen 
fibers, usually reflect direct mechanical damage to collagen 
(63). 
The amount of calcification of removed valves after long- 
term implantation is highly variable (64). Although calcifi- 
cation is noted in almost all porcine aortic valve bioprosthe- 
ses implanted for at least 4 years, valves with minimal or no 
calcific deposits are occasionally encountered after 10 years 
or more. Calcification is markedly accelerated in bioprosthe- 
ses implanted in children, adolescents, and young adults 
(1,65). 
Degenerative cuspal calcific deposits form within the 
cusps (intrinsic mineralization), and are composed of cal- 
cium phosphates, closely related to physiologic bone min- 
eral (hydroxyapatite). Calcific deposits generally predomi- 
nate at the cuspal commissures and basal attachments, are 
grossly visible as nodular gray/white masses that often ul- 
cerate through the cuspal tissue, and are most extensive in 
the porcine valve spongiosa layer. Ultrastructurally, calcific 
deposits are associated with connective tissue cells and col- 
lagen (66,67). 
Pericardial bioprostheses also suffer calcific degenerative 
failure in both adults and children (68,69). However, noncal- 
cific cuspal perforations and tears more frequently cause 
failure of clinical pericardial bioprostheses (70-72). Defects 
occur near the cuspal attachments and are usually related to 
either continuous trauma of the tissue against the Dacron 
cloth strut covering, causing abrasion (Fig. 6A), or fatigue of 
the tissue near the free edge of the leaflet, adjacent to the 
stent post (Fig. 6B). 
Other tissue valves. Noncommercial, hospital-made au- 
tologous and homologous tissue valves constructed from 
pericardium, fascia lata, or dura mater mounted on cloth- 
covered metal stents have also been used. Clinical studies 
reveal extremely high failure rates, with removed valves 
having thick connective tissue overgrowth, cuspal stiffening 
and shrinkage, calcification, and tearing (4,5,73,74). In con- 
trast, unstented, cadaver-derived aortic homografts, used for 
selected patients with isolated aortic valve disease or con- 
genital malformations, have excellent short- and medium- 
term function (75-78). Pathologic issues related to valve 
allografts are discussed below. 
Miscellaneous Valve-Related Pathology 
Prosthetic valves are not only partially obstructive to for- 
ward flow but also have some variable regurgitant flow, 
often intentionally designed into the mechanism to enhance 
closing. The increased hemodynamic burden of the resultant 
chronic pressure and/or volume overload probably con- 
tributes to progressive myocardial deterioration in some pa- 
tients. Contemporary tilting and bileaflet tilting disk valves 
and bioprostheses have favorable hemodynamic perfor- 
mance (79,80). However, bioprostheses can be significantly 
obstructive, particularly in small sizes, where the bulk of the 
struts is not proportionally reduced. Moreover, inward de- 
flection of the stent posts (stent creep) during function of 
some porcine bioprostheses may contribute to progressively 
increasing stenosis (Fig. 7) (81). Prostheses inappropriately 
large for the anatomic site of implantation can have re- 
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Figure 4. Mechanical prosthetic valve 
degenerative dysfunction. A. Distortion 
and cracking of silicone poppet of Starr- 
Edwards caged-ball prosthesis due to 
lipid absorption causing sticking in cage 
(ball variance). B. Cloth-covered 
Braunwald-Cutter caged-ball valve 
prosthesis with tearing and focal retrac- 
tion of cloth covering at the distal aspect 
of the struts. C. Disk notching of Beall 
Teflon caged-disk mitral prosthesis; 
abrasive wear has also caused exposure 
of the underlying metal of the cage (ar- 
row). D. Bjork-Shiley heart valve pros- 
thesis fracture lesser (outflow) strut pre- 
viously welded to the metal frame. 
Fracture surfaces are noted by arrows. 
The fractured strut could not be located 
at autopsy. E. Fractured carbon disk 
of Hemex-Duromedics bileaflet tilting 
disk valve. 
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stricted poppet motion, impinge on surrounding structures, 
or be obstructive, since flow around the poppet may be 
impeded (prosthetic disproportion) (82). Mitral prostheses 
too large for the ventricle into which they are placed can 
interfere with left ventricular filling or emptying. 
Factors extrinsic to a prosthesis can promote stenosis or 
regurgitation (82-95). A trend in mitral valve replacement 
surgery is the relention of as much of the mitral apparatus as 
possible, in the belief that this enhances postoperative left 
ventricular function (83). However, either retained valve 
remnants or unraveled or excessively long ends of sutures 
can interfere with valve occluder motion (Fig. 8). A large 
Figure 5. Porcine bioprosthetic valve calcific failure. A. Calcific 
stenosis, B. Calcification with secondary tear. (A and B are repro- 
duced by permission from Schoen FJ and Hobson CE. Anatomic 
analysis of removed prosthetic heart valves: causes of failure of 33 
mechanical valves and 58 bioprostheses, 198%1983. Hum Path01 
1985; 16549-559. Copyright 1985, W.B. Saunders.) 
C. Calcification, tearing and calcific embolus (arrow) removed 
from left anterior descending coronary artery. 
mitral annular calcific nodule or septal hypertrophy can pre- 
vent full excursion of a mitral tilting disk valve occluder. 
Exuberant overgrowth of fibrous tissue can obstruct the in- 
flow orifice of any valve (Fig. 9), prevent full mechanical 
valve occluder excursion, or cause stenosis or regurgitation 
of bioprostheses. Intermittent sticking of tilting disk pros- 
theses has been recognized; sometimes, such valves appear 
to function normally when removed, and the cause of mal- 
function remains obscure, despite careful pathologic exami- 
nation. Sutures may be looped around bioprosthetic valve 
stents, particularly with pericardial bioprostheses, restricting 
cuspal motion, and suture ends cut too long may perforate a 
bioprosthetic valve cusp (1). 
Some red blood cell destruction by the turbulent flow in 
prosthetic heart valves is common, but hemolysis is gener- 
ally slight and well compensated; severe hemolytic anemia 
is unusual without paravalvular leaks or valvular dysfunc- 
tion (96-98). Renal tubular hemosiderosis or cholelithiasis 
noted at autopsy suggests chronic hemolysis (99,100). 
The spectrum of morphologic changes that occurs prior 
to and following bioprosthesis implantation and the spe- 
cific differences between porcine aortic valve and bovine 
pericardium are summarized elsewhere (5,7,101-105). Sys- 
temic diseases can also involve bioprosthetic valves (106, 
107). 
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Figure 6. Noncalcific failure of bovine pericardial 
valves. A. Tear (open arrow) and incipient tear (arrow), 
due to abrasion at stent post. (Reproduced by permission 
from Schoen FJ. Pathology of bioprostheses and other 
tissue heart valve replacements. In: Silver MD, ed. Car- 
diovascular Pathology, 2nd ed. New York: Churchill 
Livingstone, 1991: 1547-1605.) B. Commissural tear. 
(Reproduced by permission from Schoen FJ. Cardiac 
valve prostheses: pathological and bioengineering con- 
siderations. J. Cardiac Surg 1987; 2:65-108. Copyright 
1991, Futura Publishing Company). 
Aortic Valve Allografts 
HomografWograft aortic valves are advantageous for 
selected patients with aortic valve disease or those requiring 
pulmonic valve and/or pulmonary artery replacement for 
congenital heart disease (375-78). Allograft aortic valve/ 
root replacement is considered a useful method for manage- 
ment of active endocarditis complicated by annular destruc- 
tion and for surgical treatment of many kinds of congenital 
heart disease where the creation of a pathway from a ventri- 
cle to the pulmonary arteries is necessary (108). Representa- 
tive failure rates are 19 to 50% at 10 to 12 years and 54 to 
89% at 15 to 20 years for variously prepared valves, includ- 
ing chemically-treated and antibiotic-sterilized allografts 
(75-78). In general, however, results for contemporary allo- 
graft heart valves appear to he somewhat better than those 
using obsolete tissue treatments, and it is well accepted that 
the time course of failure of allografts is slower than that for 
other tissue valves, especially in a young population. Thus, 
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Figure 7. Stem creep of porcine bioprosthesis. Left, a 25mm aortic prosthesis implanted for 36 
months; compromise of the outflow orifice is apparent. Right, an unimplanted 2%mm prosthesis for 
comparison. (Reproduced by permission from Schoen FJ, Schulman LJ, Cohn LH. Quantitative 
anatomic analysis of “stent creep” of explanted Hancock standard porcine bioprostheses used for 
cardiac valve reulacement. Am J Cardiol 1985: 56:110-l 14. Copyright 1985, Yorke Medical Pub- 
lishers). s 
the allograft, when available, is the replacement of choice in 
many centers. Current interest is directed toward allografts 
cryopreserved in liquid nitrogen at -196°C using dimethyl 
Figure 8. Interference with tilting disk valve occluder motion by 
suture with long cut end (arrows). (Reproduced by permission from 
Schoen FJ. Surgical Pathology of removed natural and prosthetic 
heart valves. Hum Pathol, 1987; 18:558-567. Copyright 1987, 
W.B. Saunders.) 
sulfoxide (DMSO) as a protective agent; some studies sug- 
gest that these valves perform significantly better than an- 
tibiotic-treated grafts (75,78). The major advantages of allo- 
grafts are excellent hemodynamic performance, nearly 
equivalent to that of the natural aortic valve, and an exceed- 
ingly low rate of thromboembolism (less than 4% total up to 
Figure 9. Tissue overgrowth compromising inflow orifice of 
porcine bioprosthesis. 
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15 years, compared to 1 to 4% per year for mechanical and 
bioprosthetic valves). Nevertheless, failure resulting from 
progressive degeneration occurs frequently, with incompe- 
tence the major limitation generally caused by cuspal rup- 
ture, distortion with retraction, or perforations (76,77). The 
relative advantages and disadvantages of mechanical, bio- 
prosthetic and allograft valves are summarized in Table 2. 
Allograft valves are historically obtained from cadavers, 
but many are now harvested from diseased hearts removed 
from cardiac transplant recipients. Early cadaver-derived 
allograft valves were procured aseptically and implanted 
within 1 to 3 weeks. However, due to logistical difficulties, 
valves were subsequently sterilized either chemically or by 
radiation, following nonsterile procurement. Such valves 
suffered a high rate of leaflet calcification and rupture (109- 
113). Antibiotic-sterilized but not cross-linked valves, used 
more recently, are often considered “fresh,” but they are 
essentially nonviable. Although studies suggest that some 
metabolic activity and viable cells may remain in the grafts 
at the time of implantation of valves cryopreserved using 
current technology (114), it is unknown whether allograft 
cell viability at implantation time is an important determi- 
nantof long-term durability. Impetus to achieve cell viabil- 
ity may be a search for a more “gentle” treatment of the 
valve that may preserve other important elements, such as 
extracellular matrix, irrespective of the state of the cells. 
Moreover, the presence of viable cells could be deleterious, 
for example, by potentiating immunological reactivity (115) 
or calcification. 
Pathologic features noted in removed failed or nonfailed 
aortic valve allografts are illustrated in Figure 10 and sum- 
marized in Table 3. Nearly all valves removed following 
various periods of implantation are devoid of surface en- 
dothelium and deep connective tissue cells of both valve 
cusps and contiguous aortic wall. Inflammatory cellularity is 
variable. Late explants frequently have some degree of prox- 
imal intimal fibrous sheath, aortic wall calcification and, 
occasionally, cuspal calcific deposits (116, 117). Stent- 
mounted aortic allografts used for mitral valve replacement 
Table 2. Allograft Valve Morphology 
Nearly All Valves 
Loss of cuspal connective tissue cells 
Loss of endothelium 
Minimal inflammatory cellularity 
Aortic wall calcification 
None to minimal cuspal calcification 




Suture line dehiscence 
Commissural fusion 
Mural thrombus 
Fraying of cuspal free edge 
Cuspal hematomas 








Bioprostbetic valves Less obstructive’ Less durable 
More thromboresistam 
Homograft valves Near-normal hemo- 
dynamics 
Thromboresistant 
Slightly more durable 
Limited availability 
*Except for some models. 
‘Except for small sizes. 
often show detachment of the allograft tissue from the sup- 
porting stent posts with cuspal tears (118). Calcification of 
unstented aortic valve allografts occurs predominantly in the 
contiguous aortic wall, prominently involving elastic ele- 
ments (4,116). 
Histocompatibility issues in the transplantation of heart 
valve allografts are not well established. Most allografts are 
not matched to the recipient’s ABO blood group. Neverthe- 
less, immunosuppression is generally not used. Significant 
lymphocytic infiltrate is unusual; the extent to which classi- 
cal rejection contributes to failure is unknown. 
Several tissue banks and one commercial organization are 
now procuring, processing, and distributing allograft valves 
in the United States. The Cardiovascular Devices Panel of 
the Food and Drug Administration recently developed a set 
of guidelines for heart valve allografts. Because of the 
paucity of retrieved devices and because most are removed 
at reoperations where the surgeon has difficulty removing 
the valve intact, allograft pathology has been relatively diffi- 
cult to characterize. Previous detailed reports described 
pathologic features of valves using treatments no longer 
employed (108-l 13). Consequently, pathologists receiving 
explanted clinical allografts should make every effort not 
only to address pressing patient management questions but 
also to put the underlying changes of these valves in the 
context of larger pathologic concerns. Plans are underway to 
set up an evaluation protocol and establish a central registry 
for allograft pathology. In this respect, consideration should 
be given to the use of contemporary techniques of molecular 
forensics and DNA fingerprinting to assess cell lineage is- 
sues (i.e., donor vs. recipient). 
Pathologic Analysis of Contemporary 
Valve Substitutes 
The etiology of valve failure is documented by careful 
and informed examination of artificial valves, either re- 
moved or in situ, by surgical and autopsy pathologists. Cu- 
mulative data compiled by several case studies provides the 
basis for improved valve selection criteria, patient/prosthe- 
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Figure 10. Allograft heart valve pathology. A. Aortic valve re- 
moved as a result of cuspal laxity causing insufficiency (courtesy 
William D. Edwards, M.D., Mayo Clinic). B. Aortic homograft 
used as right ventricle to pulmonary artery shunt in infant with 
congenital heart disease. The aortic wall is heavily calcified and the 
valve cusps are variably shortened and retracted (arrow). C. Typi- 
cal cuspal morphology with loss of original cellularity and few re- 
cipient inflammatory cells (hematoxylin & eosin x 175). D. Aortic 
valve homograft with loss of cuspal cells, but moderate mononu- 
clear inflammatory cellularity (hemotoxylin & eosin x 100). 
E. Immunoperoxidase staining demonstrating T-lymphocytic, 
origin of majority of cuspal cells in specimens shown in D, sug- 
gesting immunological process. (E) Immunoperoxidase using 
UCHL-1 antibody for T-lymphocytes (hemotoxylin & eosin x 
150). (C) 175X; (D) 100X; (E) 150X. 
sis matching, patient management strategies, and recogni- 
tion of complications. Informed analysis of removed clinical 
and experimental prostheses often provides data not obtain- 
able by either in vitro hemodynamic and durability tests or 
preclinical animal investigations, and elucidates mecha- 
nisms of patient-prosthesis and tissue-biomaterials interac- 
tions, thereby guiding potential improvements in valve de- 
sign and materials. Pathologists have an important role in 
recognizing prosthesis-associated complications, a key ele- 
ment of the Safe Medical Devices Act of 1990 (PLlOl-629). 
This legislation requires hospitals to report to manufacturers 
and/or the FDA incidents in which a medical device has 
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Figure 11. Opened porcine valve bioprosthesis, demonstrating superior visualization of cuspal tear. 
In this case, a catheter-induced tear was suggested. 
caused or contributed to death of or serious injury to a 
patient. 
Complete explant analysis includes gross examination 
and photography, radiography (for bioprostheses), dissec- 
tion, histologic examination, and microbiologic cultures. 
Key morphologic features are summarized in Table 4. Spe- 
cial procedures, such as functional testing, dimensional 
analyses, surface topographic measurements, biochemical 
procedures, polarized light examination, or scanning or 
transmission electron microscopy can be used judiciously in 
experimental investigations of new valve materials or con- 
figurations and in clinical studies where specific clinico- 
pathologic correlations are sought. While the anticipated 
pathology and thus the detailed protocol for analysis de- 
pends in large part on the type of prosthesis under consider- 
ation, generalized approaches to dissection of heart valve 
Table 4. Pathological Analysis of Mechanical and 
Biourosthetic Valves 














Valve identification Vegetations/ 
Calcification Organisms 
Degree Thrombi 







prostheses and documentation of their most important 
pathologic findings have been described (4,5,18). The 
specific type and model of the prosthesis may be identified 
using radiographic and morphologic keys (4,8,120). A serial 
number placed by the manufacturer that uniquely identifies 
each valve is usually hidden under the sewing ring on the 
valve base. 
In brief, a prosthesis at either autopsy or surgical removal 
is photographed from all pertinent angles and examined for 
thrombi, vegetations, exuberant tissue overgrowth, and 
structural defects. Autopsy specimens are carefully probed 
for paravalvular leaks. Mechanical heart valve prostheses 
are checked for adequacy of poppet excursion and seating, 
defects and fractures of components, asymmetries, sites of 
abrasive wear, and poppet swelling or distortion. Biopros- 
theses are gently examined to assess cuspal excursion and 
the presence of fenestrations, tears, cuspal hematomas, cal- 
cific nodules, and central migration of struts. Removing the 
valve from the stent, then opening and pinning it on cork 
aids characterization of gross cuspal pathology (Fig. 11). 
Routine morphologic analysis of bioprostheses includes ra- 
diography (we have used the Faxitron, Hewlett Packard, 
McMinnville, OR, 0.8 min x 40 KV), that aids identification 
of the prosthesis type and assessment of calcific deposits. 
Calcification is semiquantitatively graded (usually, 0 = not 
present, 1+ = mild, 2+ = moderate, 3+ = more severe, and 4+ 
= most severe), and the location of calcitic deposits noted 
(with respect to cuspal bodies, commissures, basal attach- 
ment sites, and at the free cuspal edges) (Fig. 12) (64). 
Specimens of cuspal and adherent tissue are specifically 
labeled and mounted in cross section for histologic analysis. 
Histologic analysis is directed toward determination of the 
morphology of tissue/prosthesis interactions, cuspal degen- 
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Table 5. Implant Failure Analysis 
Related to Design Feature 
High stress 
Abrasion 
Tolerances too high or too low 
Blood stasis 
Related to Stock Material/Processing 
Inclusions/bubbles/porosity 
Heterogeneity 
Weld defects/phase changes 




















Figure 12. Composite radio- 
graph of calcified porcine aortic 
valve bioprostheses, demonstrat- 
ing the various levels of mineral- 
ization, l+ through 4+, and pro- 
viding radiographic standards for 
examination. Uncalcified (0), l+, 
and 2+ (top); 3+, 3+ and 4+ (bot- 
tom). (Reproduced from Schoen 
FJ, Kujovich JL, Webb CL, Levy 
RJ. Chemically determined min- 
eral content of explanted porcine 
aortic valve bioprostheses: corre- 
lation with radiographic assess- 
ment of calcification and clinical 
data. Circulation 1987; 76: 106 l- 
1066. Copyright 1987, American 
Heart Association.) 
eration, and the degree and specific morphology of calcific 
deposits. Embedding in glycolmethacrylate allows section- 
ing of undecalcified specimens with good morphological 
preservation. 
Role of the Pathologist in Prosthetic Heart 
Valve Failure Analysis 
While not appropriate in the routine hospital setting, in- 
vestigations using highly detailed implant retrieval and anal- 
ysis elucidate mechanisms of prosthesis failure and thereby 
stimulate directed development of improved prostheses. 
Moreover, pathologists frequently participate as expert wit- 
nesses in product liability litigation involving cases of pros- 
thetic valve failure. The essential objective in either situa- 
tion is the assignment of a failure mechanism that 
distinguishes the relative roles of design, materials, fabrica- 
tion, shipping, storage, implantation, and changes during 
function (Table 5). Determination of the etiology of an out- 
let strut fracture in a Bjork-Shiley 60” convexo-concave 
tilting disk valve exemplifies general retrieval and analysis 
procedures that maximize obtainable data, without compro- 
mising further examination by other parties. This case illus- 
trates the major factors in outlet strut failure, determined 
from evaluation of more than 20 explanted fractured Bjork- 
Shiley heart valves for which all three components (annulus 
with integral inlet strut, fractured outlet strut, and disk) were 
retrieved (121). 
Outlet strut fatigue fractures in Bjork-Shiley convexo- 
concave valves have been attributed to abnormal loads and/ 
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or welding flaws (54,121). The source of these abnormal 
loads is illustrated in Figure 13A, a cross section of the valve 
through the midpoints of both the welded outlet strut (left, 
above) and integral inlet strut (right, below). Under normal 
conditions, the disc of the closed valve would be in a hori- 
zontal position and come to rest on the larger integral inlet 
strut. In the valve illustrated, abnormally high clearance 
between the inlet and outlet struts permits the disk to rotate 
in a clockwise direction beyond the horizontal plane, caus- 
ing a hard contact with the tip of the outlet strut (indicated by 
arrow). This results in excessive bending stresses at and near 
the welds joining the outlet strut to the annulus; a marker for 
this abnormal loading is a pronounced wear flat on the tip of 
the outlet strut (Fig. 13B). In some cases, contact between 
the disk and the tip of the outlet strut is manifest by localized 
pyrolytic carbon wear deposits on the inlet strut near its 
junction with the a~ulus. Such deposits result from contact 
between the inlet strut and the periphery of the disk at the 
same time that the center of the disk is contacting the tip of 
the outlet strut. In other instances, abnormal motion leads to 
two distinct overlapping wear flats on the tip of the outlet 
strut. 
The first outlet strut leg to fail invariably shows signs of 
extensive abrasion and wear resulting from the relative mo- 
tion of the halves of this fractured strut as fatigue fracture of 
the second strut leg is occurring. Low magnification scan- 
ning electron micrographs of the fracture surfaces of the first 
and second strut leg to fail are shown in Figures 13C and 
13D, respectively; slip bands from bending during manufac- 
ture are also evident on both strut legs. Both fractures ini- 
tiated on the inlet side of the outlet strut, as in other valves 
that fractured. The first strut leg fracture typically initiates at 
or near the point of maximum bending stress in the center of 
the inlet strut leg/annulus junction. The initiation site in the 
second strut leg to fracture is often rotated slightly toward 
the first, since the remaining intact strut leg is subjected to 
both bending and torsion after the first fracture occurs. 
Observations on the sides of an annulus and strut leg that 
have fractured are often useful in evaluating the mechanism 
of fatigue fracture and its relationship to microstructure and 
material flaws, especially in situations where there has been 
extensive abrasion and wear of the mating fracture surfaces 
of the initially fractured strut leg. Secondary cracks below 
the heavily abraded fracture surface of the first strut leg to 
fracture are associated with weld shrinkage porosity and/or 
inclusions (Fig. 13E). 
Standards for use by experts in the product liability sys- 
tem developed by ASTM Committee E-40 on Technical 
Aspects of Product Liability Litigation are recommended for 
such analyses, including ASTM E-620-85(90) and E-678-84 
(American Society for Testing and Materials, Philadelphia, 
PA). The detail shown in the above micrographs can only be 
observed if the devices are carefully preserved after explan- 
tation, particularly avoiding contact between fracture sur- 
faces, since wear patterns clearly provide valuable insights 
into the mechanism of failure. Destructive testing, such as 
sectioning, polishing, and etching the housing metal alloy, is 
useful in characterizing the valve microstructure and its rela- 
tionship to fracture. However, such destructive testing 
should proceed only after all interested parties have had an 
opportunity to complete nondestructive tests, since potential 
observations may be precluded. 
Pathohiology of Bioprosthetic 
Valve Calcification 
In both circulatory and subcutaneous experimental mod- 
els, bioprosthetic tissue calcifies progressively, with mor- 
phologic features similar to those observed in clinical spec- 
imens, but with markedly accelerated kinetics (122-124). 
Valves implanted into sheep or calves calcify extensively in 
3 to 6 months, and subcutaneous implants of bioprosthetic 
tissue in young rats achieve calcium levels comparable to 
those of failed clinical explants in 8 weeks or less. We have 
utilized the subcutaneous implantation model extensively as 
a technically convenient, economically advantageous, and 
quantifiable model for investigating host and implant deter- 
minants and pathobiology of mineralization, as well as for 
screening and understanding the mechanisms of potential 
strategies for mineralization inhibition (122-131). 
Clinical and experimental studies indicate that calcifica- 
tion of bioprosthetic valves depends on host, implant, and 
biomechanical factors ( 1,4,122,132). Although calcification 
is most pronounced in areas of leaflet flexion, where defor- 
mations are maximal (i.e., cuspal commissures and bases), 
dynamic mechanical stress and strain are not prerequisites 
for calcification. Young age and renal failure potentiate min- 
eralization, but the specific basis for age-dependent kinetics 
is uncertain (122,132). In rat subcutaneous implants, calcifi- 
cation requires pretreatment of tissue with an aldehyde 
cross-linking agent; nonpreserved cusps do not mineralize in 
this model (122,126). Glutaraldehyde-treated porcine aortic 
valve and bovine pericardium calcify comparably with re- 
spect to kinetics, extent, and morphology (123,124). This 
suggests that the fundamental mechanisms of bioprosthetic 
tissue mineralization depend on specific biochemical modi- 
fications of implant microstructural components induced by 
aldehyde pretreatment. 
Neither nonspecific inflammation nor specific immuno- 
logic responses appear to mediate bioprosthetic tissue calci- 
fication(l22,125). Thetissuereactionassociatedwithcircula- 
tory and subcutaneous porcine orpericardial valve implants 
is a classical foreign body reaction, primarily composed of 
nonlymphocytic mononuclear cells (i.e. macrophages) 
(4,122). Although several experimental studies have sug- 
gested that bioprosthetic tissue can be immunogenic, despite 
both high collagen content and cross-linking (133,134), 
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Conlaci between tip 
of outlet strut and disc 
during valve closure. 
Figure 13. Bjork-Shiley convexo-concave valve 
fracture analysis (B-E are scanning electron 
micrographs). A. Cross section through center 
of valve showing contact between tip of outlet strut 
(cross-hatched circle) and disk (black) during valve 
closure. Contact area is indicated by arrow. 
1 B. Elliptical wear flat on tip of outlet strut 




C. Worn and abraded fracture surface 
leg to fracture. Origin is at the bottom 
bands from deformation during manuf 
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D. Fracture surface of second strut leg to fracture. 
Absence of pronounced wear and slip bands is 
apparent. 
(W 
E. Slide of annulus near origin of fracture (top). 
Welding porosity and secondary cracking are 
present on the side of the annulus. 
46 SCHOEN ET AL. CVP Vol. 1. No. I 
PATHOLOGICAL CONSIDERATIONS IN REPLACEMENT CARDIAC VALVES January-March 1992:29-52 
0.2 - 
Figure 14. Effects of preincuba- p 
tion in 1% SDS on calcification .c 
in a rat subcutaneous model of g 
glutaraldehyde cross-linked por- P 
tine aortic valve. These results O 
support the concept that phos- 
pholipid extraction is an impor- 
; 
tant but perhaps not the only 
z 
2 
mechanism of SDS efficacy. ;i 
W 
0 
there is no evidence that immunological reactivity is causal 
to mineralization. 
The earliest mineral deposits in both clinical and experi- 
mental bioprosthetic tissue are localized to transplanted con- 
nective tissue cells; collagen involvement occurs later (122- 
124). As the implant period increases, cell-associated 
deposits increase in size and number, obliterating cells and 
dissecting among collagen bundles. Analogous to clinical 
valve failures, gross nodules focally obliterate implant ar- 
chitecture and ulcerate through the cuspal surface (123,124). 
Mineralization of the connective tissue cells of biopros- 
thetic tissue is hypothesized to result from glutaraldehyde- 
induced cellular devitalization and the resulting disruption 
of cellular calcium regulation (124). Intact living animal 
10 20 
Time in SDS (Hours) 
30 
cells have low intracellular free calcium concentration (ap- 
proximately 10.‘M), while extracellular free calcium is 
much higher (approximately 10e3M), resulting in a 10,000 
fold gradient across the plasma membrane. In healthy cells, 
cellular calcium is maintained low by energy-requiring 
metabolic processes, including the plasma membrane-bound 
Ca”-ATPase, and intracellular binding by soluble cytosolic 
Figure 15. Heavily calcified experimental polyurethane mitral 
trileaflet heart valve removed from sheep following 5 months im- 
plantation. A. Gross photo from distal aspect. B. Photomi- 
crograph of extrinsic calcific deposits on cusp. (von Kossa stain 
[calcium phosphates black] x 175.) 
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or membrane-bound proteins. Moreover, the observed sites 
of nucleation of bioprosthetic tissue mineralization (i.e, or- 
ganellar and plasma membranes), contain considerable 
phosphorus, largely in the form of phospholipids. We hy- 
pothesized that passive calcium entry occurs unimpeded in 
cells modified by aldehyde cross-linking, but the mecha- 
nisms for calcium removal are dysfunctional. In this model, 
calcium influx contributes to apatite formation by reacting 
with compartmentalized, bound phosphorus. In support of 
the above hypothesis, we have demonstrated, using a newly 
available technique called electron energy loss spectroscopy 
(EELS), focally high concentrations of intracellular phos- 
phorus in unimplanted, glutaraldehyde-preserved porcine 
aortic valve and bovine pericardium, and the progressive 
accumulation of calcium in tissues that have been implanted 
(131). The formation of calcium phosphate deposits occurs 
at these cellular sites as early as two days following implan- 
tation in the rat subcutaneous model. It is unknown whether 
collagen deposits are related to contiguous cell-oriented 
mineral deposition, or arise independently. 
Pathologic calcification in the calcific diseases (e.g., de- 
generative calcific aortic stenosis, atherosclerosis) and the 
normal calcification of skeletal and dental tissues share im- 
portant features: 1) initial mineral deposits are poorly crys- 
talline apatitic mineral, highly insoluble in body fluids at 
physiological pH, but able to proliferate in serum concentra- 
tions of calcium and phosphate; 2) cell and collagen crystal 
deposits are ultimately present, and 3) initial crystal forma- 
tion occurs on cell membranes, usually in the form of extra- 
cellular vesicles (132,135-l 39). Interestingly, alkaline 
phosphatase, a matrix vesicle-associated enzyme critical to 
bone mineral nucleation, is present in both fresh and fixed 
bioprosthetic tissue, localized to sites where early mineral- 
ization occurs (140,141). Alkaline phosphatase further accu- 
mulates in porcine aortic valve tissue, in both subcutaneous 
and circulatory sites, concurrent with mineralization onset 
(141). 
Enhancement of Bioprosthetic 
Valve Durability 
Several approaches are under investigation to reduce bio- 
prosthetic valve failure by modifying host, implant, or me- 
chanical influences. Modifications in cuspal configuration, 
valve design and tissue pretreatment procedures might en- 
hance overall durability through lower mechanical stresses, 
thereby lessening structural damage, as well as reducing 
calcification. 
Strategies for prevention of bioprosthetic tissue mineral- 
ization involve modifications of either valve preparation 
details or the local environment of the implant (132). Mech- 
anisms of calcification inhibition by antimineralization 
treatments (AMTs) considered and/or investigated, clini- 
cally and/or experimentally, include extraction of calcifiable 
material, ionic and/or macromolecular binding to nucleation 
Table 6. Anticalcification Studies-Sheep, Mitral, 5 Mos 
Treatment Type N Ca (Wmg) 
Control (none) PAV 22 99.8 +/- 11.1 
Control (none) BPV 17 104.3 +/- 9.1 
Polysorbate-80 (PV2) PAV 15 7.6 +I- 2.6 
Polysorbate-80 (PV2) BPV 11 55.2 +I- 12.7 
Triton X-100, N-laurel sarcosine (PV2’) PAV 17 24.4 +I- 1.8 
Polyacrylamide (PV3) PAV 8 112.9 +/- 15.3 
SDS (T6) PAV 17 17.7 +I- 4.2 
SDS (T6) BPV 24 126.6 +I- 5.3 
APDP BPV 12 126.6 +I- 7.3 
Toluidine blue PAV 21 81.6 +I- 12.0 
PAV, porcine aortic valve; BPV, bovine pericardial valve. Modified 
from M Jones et al. J Cardiac Surg 4:69, 1989. 
sites, neutralization of critical cofactors, such as alkaline 
phosphatase (141), interference with calcium phosphate 
crystal growth, charge modification, alteration of interstitial 
tissue spaces by tissue compression or hydrogel infiltration, 
prevention of serum diffusion into cusps, and restoration of 
natural inhibitors. Diphosphonate compounds, used to treat 
metabolic bone disease, retard calcium phosphate crystal 
growth. In rats with subcutaneously implanted bioprosthetic 
tissue, either systemic therapy with ethanehydroxydiphos- 
phonate (EHDP) or EHDP administered in the vicinity of the 
valve tissue from controlled-release drug delivery polymers 
loaded with the drug inhibit leaflet calcification (127-130). 
Cuspal modification by incubation in solutions of trivalent 
ions of aluminum or iron (A13’ or Fe3’) (131), elements 
associated with osteomalacia in renal dialysis patients (142), 
also inhibits mineralization. Our studies suggest that mitiga- 
tion of mineralization derives from the association of alu- 
minum or iron ions with devitalized cells, the sites of initial 
calcification (13 1). Although pretreatment in sodium dode- 
cyl sulfate (SDS) also significantly inhibits calcification of 
porcine aortic valve tissue implanted subcutaneously in rats, 
results in experimental circulatory models have been incon- 
sistent (143-146). Nevertheless, detergents, including SDS, 
are the only AMTs that have been demonstrated to be effec- 
tive in circulatory implants (Table 6). Likely mechanisms of 
action of SDS could include the removal of phospholipids 
(Fig. 14), charge modification, or membrane-protein denatu- 
ration. Other compounds under investigation include -cova- 
lently-linked protamine (147) and locally-administered 
phosphocitrate, a natural calcification inhibitor (148). 
Preclinical determination of the efficacy and safety of 
AMTs includes four components: 1) initial qualification us- 
ing heterotopic implantation (e.g., subQ in rats); 2) hydrody- 
namic/durability testing (e.g., pulse simulator, pulse acceler- 
ator); 3) morphologic studies of unimplanted material to 
assess treatment-induced degradation, and 4) valve replace- 
ment in an animal model. Clearly, however, bioprosthetic 
heart valve durability can be assessed with certainty only by 
long-term (>lO years) clinical evaluation. Efficacy and 
safety must be demonstrated for any strategy (Table 7). 
48 SCHOEN ET AL. CVP Vol. 1. No. 1 
PATHOLOGICAL CONSIDERATIONS IN REPLACEMENT CARDIAC VALVES January-March 1992~29-52 
Table 7. Bioprosthetic Heart Valve Antimineralization 
Treatments: Criteria for Efficacy and Safety 
Efficacy 
Effectively inhibits calcification 
valve has adequate performance (i.e., unimpaired hydrodynamics and 
durability) 
Determination of specific mechanisms of action 
Dose-response relationship established 
Effect not lost or inactivated during function 
Neutralized component not reaccumulated 
Does not merely delay onset of mineralization 
Safety: Does Not 
Cause adverse blood-surface interactions 
hemolysis 
platelet adhesion 
coagulation protein activation 
complement activation 
inflammatory cell activation 
binding of vital serum factors 
Enhance local or systemic inflammation 
foreign body reaction 
immunological reactivity 
hypersensitivity 
Cause local or systemic toxicity 
Potentiate infection 
Other Developments 
Since aortic valve replacement with relatively small 
valves may leave unacceptable gradients, attempts are being 
made to develop a stentless porcine aortic valve bioprosthe- 
sis (149). Such a valve would be glutaraldehyde-pretreated 
using conventional technology, and implanted inside the 
aorta, thereby using the aortic root as the valve stent. This 
could not only greatly improve hemodynamics by allowing 
use of a larger valve but might improve durability by damp- 
ening cuspal mechanical stresses. Other developments in- 
clude the use of low- or zero-pressure fixation and AMTs in 
commercial porcine valves presently in clinical trials 
(150,15 1) and a custom-fabricated autologous pericardial 
valve with a novel stent construction (152). 
Modest development of mechanical prostheses with new 
designs, particularly those using pyrolytic carbon occluders, 
has continued over the past decade, but it is unlikely that 
radical design changes will be soon forthcoming. Modifica- 
tion of tilting-disk configurations has concentrated on en- 
hancing opening to improve hemodynamics, developing 
more durable supporting structures for the poppet, and re- 
ducing thromboembolic risk by eliminating metallic struts 
from regions of stasis. 
Attempts are being made to develop near-anatomic-con- 
figuration central flow trileaflet prostheses using synthetic 
polymers. Despite previous lack of success of synthetic 
trileaflet valves, due to poor tear resistance and calcification 
of the cusps (4,132), reconsideration of the concept is now 
encouraged by major developments in the technology of 
polymeric materials, with implanted polyurethanes and 
other materials. Nevertheless, long-term durability limita- 
tions remain the major concern, with valve failures marked 
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